<div id="readability-page-1"><div><p>JPMorgan issued a research report stating that AKESO (09926.HK)<span> </span><span> +4.800 (+3.756%)  </span> <span> Short selling $33.31M; Ratio 8.085%  </span> 's partner Summit Therapeutics Inc. (SMMT.US)<span> </span>  <span> </span>   recently announced that the interim progression-free survival analysis of the HARMONi-3 squamous cohort did not reach statistical significance. The news dragged Summit Therapeutics Inc.'s share price down by about 25% last Friday (1st). The bank believes the interim analysis missing the target does not represent a major negative surprise, as the statistical threshold set in the trial design was relatively high. The final progression-free survival analysis is expected to be conducted in 2H26, with a relatively high probability of success.</p><p>JPM maintains its Overweight rating on AKESO, with a TP of HKD162, based on a discounted cash flow valuation, assuming a weighted average cost of capital of 9.6% and a terminal growth rate of 3%. (ec/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-05 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)</p></div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p></div>

SMMT

SBIO

<p>JPMorgan's research report indicates that AKESOis likely to meet its final analysis target for lung cancer trials, despite a recent interim analysis by partner Summit Therapeutics Inc.showing no statistical significance, which caused a 25% drop in Summit's share price. JPM maintains an Overweight rating on AKESO with a target price of HKD162, citing a high probability of success for the final analysis expected in 2H26.</p>

AASTOCKS News

Summit Therapeutics

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VG Health

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

JPMorgan Chase

AKESO

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: AKESO  Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight